Carbamazepine and Its Metabolites in Human Perfused Placenta and in Maternal and Cord Blood

Summary: Placental transfer and metabolism of carbamazepine (CBZ) was studied in a dual recirculating placental cotyledon perfusion system and was also evaluated in 16 pairs of maternal venous and cord blood samples. Among the parameters studied as possible indicators of a successful perfusion, volume changes in perfusate divided the perfusions into two groups, whereas no significant differences between perfusions were noted in blood gas analysis or in antipyrine transfer. CBZ added into the maternal circulation crosses the placenta in the beginning quicker than antipyrine which is in agreement with the different lipid solubilities of these compounds. Because the transfer rates of antipyrine and CBZ were about the same, the mechanism of transfer of CBZ is probably similar to that of antipyrine (passive diffusion). No metabolites of CBZ could be detected in the perfusate by high‐performance liquid chromatography (HPLC) or gas chromatographyhass spectrometry. With the improved HPLC methodology for CBZ metabolites, six metabolites were detected in clinical samples, including 10‐hydroxy‐10, 11‐dihydro‐CBZ (10‐OH‐CBZ), which has been described earlier in only 1 uremic patient. Relative levels of metabolites showed significant individual differences. CBZ crosses perfused placenta rapidly, but this does not contribute to CBZ metabolites detected in maternal and fetal circulation.

[1]  S. Pynnönen,et al.  Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. , 2009, Acta pharmacologica et toxicologica.

[2]  A. Frigerio,et al.  Carbamazepine: biotransformation. , 1975, Advances in neurology.

[3]  R. K. Miller,et al.  Human placenta in vitro: characterization during 12 h of dual perfusion. , 1985, Contributions to gynecology and obstetrics.

[4]  T. Winkler,et al.  The metabolism of 14C-oxcarbazepine in man. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  M. Soma,et al.  Fetus-specific expression of a form of cytochrome P-450 in human livers. , 1990, Biochemistry.

[6]  G. Spiteller,et al.  A new carbamazepine metabolite in uraemic filtrate. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  J. Jolkkonen,et al.  Absence of interaction between oxcarbazepine and erythromycin , 1992, Acta neurologica Scandinavica.

[8]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[9]  M. Pirmohamed,et al.  The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. , 1992, Biochemical pharmacology.

[10]  S. Johannessen.  Pharmacokinetics of Anti-epileptic Drugs and their Clinical Significance. , 1990, Behavioural neurology.

[11]  A. Cailleux,et al.  Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. , 1991, Clinical chemistry.

[12]  L. Sarkozi,et al.  A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, inulin, and antipyrine. , 1983, American journal of obstetrics and gynecology.

[13]  G. R. Cannell,et al.  MARKERS OF PHYSICAL INTEGRITY AND METABOLIC VIABILITY OF THE PERFUSED HUMAN PLACENTAL LOBULE , 1988, Clinical and experimental pharmacology & physiology.

[14]  S. Pendlebury,et al.  Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. , 1987, Clinical and experimental neurology.

[15]  D. Maulik,et al.  Bidirectional Transfer of α-Aminoisobutyric Acid by the Perfused Human Placental Lobule , 1984 .

[16]  K. Jones,et al.  Pattern of malformations in the children of women treated with carbamazepine during pregnancy. , 1989, The New England journal of medicine.

[17]  H. Glatt,et al.  Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity , 1975, International journal of cancer.

[18]  D. Lindhout,et al.  The 10,11‐Epoxide‐10,11‐diol Pathway of Carbamazepine in Early Pregnancy in Maternal Serum, Urine, and Amniotic Fluid: Effect of Dose, Comedication, and Relation to Outcome of Pregnancy , 1993, Therapeutic drug monitoring.

[19]  T. Tomson,et al.  Carbamazepine Metabolism in Man , 1985, Clinical pharmacokinetics.

[20]  J. Challier,et al.  In vitro perfusion of human placenta. V. Oxygen consumption. , 1976, American journal of obstetrics and gynecology.

[21]  J. Challier.  Criteria for evaluating perfusion experiments and presentation of results. , 1985, Contributions to gynecology and obstetrics.

[22]  M. Horning,et al.  Metabolism of carbamazepine. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[23]  D. Treiman,et al.  Simultaneous high-performance liquid chromatographic determination of carbamazepine and its principal metabolites in human plasma and urine. , 1988, Therapeutic drug monitoring.

[24]  S. Schenker,et al.  Acyclovir transport by the human placenta. , 1992, The Journal of laboratory and clinical medicine.

[25]  T. Tomson,et al.  Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide , 1986 .

[26]  P. Kaufmann.  Influence of ischemia and artificial perfusion on placental ultrastructure and morphometry. , 1985, Contributions to gynecology and obstetrics.

[27]  L. Prescott,et al.  Rapid gas‐liquid chromatographic estimation of antipyrine in plasma , 1973, The Journal of pharmacy and pharmacology.

[28]  J. Dancis,et al.  Transfer across the perfused human placenta of antipyrine, sodium and leucine. , 1972, American journal of obstetrics and gynecology.